Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Gains from Sales and Divestitures: 2015-2024

Historic Gains from Sales and Divestitures for Viking Therapeutics (VKTX) over the last 10 years, with Dec 2024 value amounting to $1.6 million.

  • Viking Therapeutics' Gains from Sales and Divestitures fell 52.03% to $744,017 in Q3 2025 from the same period last year, while for Sep 2025 it was $744,017, marking a year-over-year decrease of 52.03%. This contributed to the annual value of $1.6 million for FY2024, which is 97.55% up from last year.
  • Latest data reveals that Viking Therapeutics reported Gains from Sales and Divestitures of $1.6 million as of FY2024, which was up 97.55% from $785,105 recorded in FY2023.
  • Viking Therapeutics' 5-year Gains from Sales and Divestitures high stood at $1.6 million for FY2024, and its period low was $128,859 during FY2020.
  • For the 3-year period, Viking Therapeutics' Gains from Sales and Divestitures averaged around $915,226, with its median value being $785,105 (2023).
  • Data for Viking Therapeutics' Gains from Sales and Divestitures shows a peak YoY surged of 121.70% (in 2020) over the last 5 years.
  • Over the past 5 years, Viking Therapeutics' Gains from Sales and Divestitures (Yearly) stood at $128,859 in 2020, then soared by 109.58% to $270,063 in 2021, then soared by 51.66% to $409,569 in 2022, then surged by 91.69% to $785,105 in 2023, then spiked by 97.55% to $1.6 million in 2024.